Horizon Europe

Framework programme for research and innovation 2021–2027

European Commission

VINNOVA

For updated and complete information refer to the original topic text on the Funding and Tenders portal.

The Horizon framework programme is a **POLITICAL INSTRUMENT** where research and innovation are needed to achieve political priorities

European Commission

VINNOVA

Horisont Europa



European Commission

VINNOVA

Some overarching issues

- Any legal entity established in the United States of America is eligible to receive Union funding. (all topics)
- Lump sum: a different type of budget, no reporting of actual costs
- Blind evaluation: organisations not to be disclosed in 1st stage (short) proposal
- The active involvement of relevant stakeholders (e.g. patients, civil society, clinicians, regulators) is strongly encouraged (most topics)
- Contribution of social sciences and humanities (SSH) disciplines (most topics)
- The participation of start-ups, micro, small and medium-sized enterprises (SMEs) is encouraged (many topics)
- For clinical studies a specific template should be used (whenever a clinical study is proposed)
- Subject to restrictions for the protection of European communication networks (some topics)
  Entities that are assessed as high-risk suppliers of mobile network communication equipment (and any entities they own or control) are not eligible to participate. More info in Annex B

Participation of non-EU-countries

- **Associated countries**
  Participate under equivalent conditions as legal entities from the EU Member States, unless otherwise specified.
  Third countries automatically eligible for funding (if not subjected to EU restrictive measures)
  Include many low- and middle-income countries

A full list of associated countries and third countries eligible for funding is found here

- **Other third countries**
  Can usually participate in projects ***at their own cost*** (unless otherwise specified)
  In exceptional cases they can be eligible for funding

Support

Sweden

National Contact Points:

Nadine Schweizer nadine.schweizer@vinnova.se

Susanne Frykman: susanne.frykman@vr.se

Aiga Giangiacomo Aiga.Giangiacomo@forte.se

Vinnova's Planning grant for international proposals

Closing dates: 14 May and 10 September

European Commission

Prepublication of the work programme

Info-day 22 May

EU Funding & Tenders Portal

Research Enquiry Services

European Commission

VINNOVA

Agenda

10:00 – 10:45
Staying healthy in a rapidly changing society
AND
Living and working in a health-promoting environment

11:00 – 11:45
Tackling diseases and reducing disease burden

Break

13:00 – 13:45
Ensuring equal access to innovative, sustainable, and high-quality healthcare
AND
Developing and using new tools, technologies and digital solutions for a healthy society

14:00 – 14:45
Maintaining an innovative, sustainable, and competitive EU health industry

European Commission

Overview

HORIZON-CL1-2025-03-STAYHLTH-XX-two-stage

- 1 topic
- two-stage: opening 22 May 2025, closing 1st stage 16 Sept 2025, 2nd stage 16 April 2026
- Total budget: 40 MEUR (5 projects)

Impacts:

- Citizens develop healthier lifestyles, behviors and choices and maintain a longer, independant and active life
- Citizens incl. children and adolescents, are empowered to effectively manage their physical and mental health and wellbeing
- Society benefits from reduced economic and health burdens
- Citizens' trust in knowledge-based health interventions and in guidance from health authorities is strengthened, and health literacy improved
- Health policies and actions for health promotion and disease prevention are knowledge-based, people-centred, personalised and designed to reduce health inequalities

HORIZON-HLTH-2025-03-STAYHLTH-01-two-stage: Improving the quality of life of persons with intellectual disabilities and their families

RIA, indicative budget 40 MEUR, 5 projects

Specificities: blind evaluation, lump sum, SSH

- Empowerment of persons with intellectual disabilities and their families to independance and improved quality of life
- human-centred innovations (medical, technological, other) for persons with long-term intellectual disabilities and their formal and informal carers
- paying attention to sex and gender-related differences, diagnostic biases and vulnerabilites
- Early diagnosis and intervention, comorbidities, remove barriers for participation, reduction of burden on informal carers
- Integrated care strategies
- Special attention to persons with multiple disabilities and need of adapted and special care (medical, social, educational and psychological)
- Guidance and training for formal and informal carers
- Cluster 2 topic HORIZON-CL2-2025-01-TRANSFO-09: “Good practices for increased autonomy of persons with disabilities, including physical, mental, intellectual and sensory disabilities”, synergies encouraged

Overview

HORIZON-CL1-2025-03-ENVHLTH-XX-two-stage

- 2 topics
- two-stage: opening 22 May 2025, closing 1st stage 16 Sept 2025, 2nd stage 16 April 2026
- Total budget: 80 MEUR (6, resp. 5 projects)

Impacts:

- Environmental, occupational, social, economic, and health policies and practices at the EU, national and regional level are sustainable and based on solid scientific evidence
- The health threats and burden resulting from hazardous chemicals and air, water and soil pollution and contamination are lessened
- Living and working environments are healthier, more inclusive, safer, resilient and sustainable
- The adaptive capacity and resilience of populations and health systems in the EU to climate and environmental change are strengthened
- Citizens' health and wellbeing are protected and promoted, inequalities related to environmental pollution and degradation are prevented, incl. citizens' understanding of complex environment and health issues

HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage: The impact of pollution on the development and progression of brain diseases and disorder

RIA, indicative budget 40 MEUR, 6 projects

Specificities: blind evaluation, JRC, ECHA or other relevant EU agency may participate, Galileo/EGNOS, lump sum, SSH

- Evidence-based support to global and EU policies preventing and reducing
- Citizens' protection and insight into exposure, behavioral change to support brain health
- evidence on the causal link between exposure to pollutants (focusing on specific pollutants or a combination) and the development or progression of neurological, neurodegenerative or neurodevelopmental diseases or disorders (exposome approach, incl. low-level exposure)
- pathogenesis and biological mechanisms involved in the onset and progression of disease, considering emerging pollutants
- Develop health indicators to inform mitigation and prevention measures (intersectional approach)
- Nutrition not in scope (separate topic under CL6: HORIZON-CL6-2025-02-FARM2FORK-12: "Nutrition and Mental Health"
- Large amount of related ongoing initiatives!
- Projects under the topic will form a portfolio (around 2% of the requested budget to portfolio activities)

HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage: Advancing knowledge on the impacts of micro- and nanoplastics on human health

RIA, indicative budget 40 MEUR, 5 projects

Specificities: blind evaluation, JRC, ECHA or other relevant EU agency may participate, Galileo/EGNOS, lump sum, SSH

- optimisation, validation and standardisation of the analytical methods, protocols and methodologies for collecting, detecting and quantifying environmental prevalence and exposure
- causal mechanisms of action and pathways involved on molecular, cellular and organism level effects
- Develop *in-vivo*, *in-silico* and in-vitro models, instruments and methods for risk and hazard assessment, harmonised across various types of MNPs, incl. long-term exposure and real-world scenarios
- Human biomonitoring, dosimetry, interaction with other pollutants and combined impacts
- Delivery, degradation and elimination processes, incl. microbiome
- Projects under the topic will form a portfolio (around 2% of the requested budget to portfolio activities)

Agenda

10:00 – 10:45
Staying healthy in a rapidly changing society
AND
Living and working in a health-promoting environment

11:00 – 11:45
Tackling diseases and reducing disease burden

Break

13:00 – 13:45
Ensuring equal access to innovative, sustainable, and high-quality healthcare
AND
Developing and using new tools, technologies and digital solutions for a healthy society

14:00 – 14:45
Maintaining an innovative, sustainable, and competitive EU health industry

European Commission

Expected impact

- Disease burden in the EU and worldwide is reduced through effective disease management,
- Premature mortality from non-communicable diseases is reduced by one third (by 2030), mental health and wellbeing are promoted, and the related disease burden (Disability-Adjusted Life Years - DALYs) is reduced
- Healthcare systems benefit from strengthened Research and Innovation expertise, human capacities and know-how
- Citizens benefit from reduced (cross-border) health threat of epidemics and AMR pathogens, in the EU and worldwide
- Patients and citizens are knowledgeable of disease threats, involved and empowered to make and shape decisions for their health

Overview

Call opening
22 May

HORIZON-HLTH-2025-01-DISEASE-01: Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections	RIA	**Single stage** **Deadline:** **16 Sep 2025** Total budget: 182 MEUR
HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential	RIA	
HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response	RIA	
HORIZON-HLTH-2025-01-DISEASE-05: Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)	CSA	
HORIZON-HLTH-2025-01-DISEASE-06: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)	RIA	
HORIZON-HLTH-2025-01-DISEASE-07: Tackling high-burden for patients and under-researched medical conditions	RIA	
HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders	RIA	**Two-stage** **Deadlines:** **1: 16 Sept.** **2: 16 April 2026** Budget:50 MEUR

HORIZON-HLTH-2025-01-DISEASE-01: Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections

RIA, Single-stage, Indicative budget 45 MEUR, 3 projects

Specificities: Lump-sum Subject to restrictions for the protection of European communication networks.

- Develop phage-based therapies to treat bacterial infections that do not respond to conventional treatment options
- Perform multicenter, multinational randomised controlled clinical trial (RCT) to generate scientific evidence demonstrating safety and efficacy (alone or in combination)
- Applicants are encouraged to address pathogens listed in the WHO Bacterial Priority Pathogens List
- The use of computational modelling and/or artificial intelligence (AI) tools is encouraged
- Regulatory approval within 12 mo from the start of the project

HORIZON-HLTH-2025-03-DISEASE-02-two-stage: Advancing innovative interventions for mental, behavioural and neurodevelopmental disorders

RIA, Two-stage, Indicative budget 50 MEUR, 7 projects

Specificities: Blind evaluation pilot (first stage). Lump-sum. Subject to restrictions for the protection of European communication networks.

- Perform rigorous clinical studies into the safety and efficacy of therapeutic solutions based on active substances and other non-invasive multidisciplinary and/or transdiagnostic approaches
- The disorders in scope: Chapter 6 of the International Classification of Diseases (ICD11) . Rare diseases are excluded.
- Through the clinical studies, gain further insight into the mechanism(s) of action
- Use and/or develop technologies, to help implement and monitor the long-term efficacy and disease progression
- Leverage already existing and emerging state-of-the-art research infrastructures

HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential

RIA, Single-stage, Indicative budget 50 MEUR, 5 projects

Specificities: Lump-sum

- Development of existing antiviral and prophylactic and therapeutic candidates that are based on antibody and/or antibody-derived proteins targeting at least one of the priority viruses
- If necessary, finalisation of the in vitro characterisation
- In vivo tests in at least one animal model (and if necessary in a non human primate model)
- Production of GMP quality test batches
- First in human clinical safety studies
- Participation of third countries where the viruses are endemic or where outbreaks have occurred or are ongoing is encouraged
- Leverage already existing and emerging state-of-the-art research infrastructures

HORIZON-HLTH-2025-01-DISEASE-04: Leveraging artificial intelligence for pandemic preparedness and response

RIA, Single-stage, Indicative budget 35 MEUR, 5 projects

Specificities: Subject to restrictions for the protection of European communication networks.

- Develop new, or improve existing AI-based tools, methods and technologies for more safe, efficient and impactful countermeasures aiming at the prevention, containment or control of infectious disease
- Scout, assemble and prepare appropriate FAIR datasets generated across the EU and Associated Countries
- Leverage the capacities of the existing and emerging data research infrastructures, EHDS, EOSC
- Identify and address the current technical, operational, and social limitations
- Detecting and mitigating gender, ethnicity and other biases,

HORIZON-HLTH-2025-01-DISEASE-05: Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)

CSA, Single-stage, Indicative budget 2 MEUR, 1 project

Specificities: Lump-sum

- GloPID-R Platform for coordination between funders and with relevant global actors such as the WHO or the Coalition for Epidemic Preparedness Innovation (CEPI)
- Administrative, technical and scientific support through a secretariat
- Support the GloPID-R board, working groups and advisory bodies
- Internal and external dissemination and communication

HORIZON-HLTH-2025-01-DISEASE-06: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)

RIA, Single-stage, Indicative budget 20 MEUR, 6 projects

- Global Alliance for Chronic Diseases (EC and other global funders)
- Strengthening health systems for equitable high-quality care and health outcomes in the context of NCDs in LMICs and/or disadvantaged populations of HICs setting
- Implementation of intervention(s) for a selected study population(s) taking into account the unique social, political, economic, and cultural context(s)
- Address health equity and the principles of Universal Health Coverage
- Equitable partnership and shared leadership
- Capacity building, include at least one early career member as a co-investigator.

HORIZON-HLTH-2025-01-DISEASE-07: Tackling high-burden for patients and under-researched medical conditions

RIA, Single-stage, Indicative budget 30 MEUR, 5 projects

Specificities: Grants will be awarded to proposals not only in order of ranking but also in function of the highest ranked proposals in different medical conditions

- Examples: Myalgic encephalomyelitis/chronic fatigue syndrome, autism, gynaecological diseases, low back pain… Rare diseases are not in scope
- Multidisciplinary approaches and a broad representation of stakeholders in the consortia
- Identifying the pathophysiological mechanism(s) and potential risk factors
- Sex and gender-related aspects, age, ethnicity, socio-economic, lifestyle and behavioural factors
- Development of biomarkers and/or model systems should be considered
- Expected to include clinical studies
- Exploitation of existing data, biobanks, registries and cohorts, generation of new data

HORIZON-HLTH-2025-02-DISEASE-01: European Partnership for Brain Health

Programme Co-fund Action, Single-stage, Indicative budget 150 MEUR, 1 project

Vetenskapsrådet and Forte will join the partnership

HORIZON-HLTH-2025-02-DISEASE-02: European partnership fostering a European Research Area (ERA) for health research (Phase 2)

Programme Co-fund Action, Single-stage, Indicative budget 77 MEUR, 1 project

Vetenskapsrådet will join the partnership

Specificities: Beneficiaries may provide financial support to third parties in the form of grants, The funding rate is up to 30% of the eligible costs.

Agenda

10:00 – 10:45
Staying healthy in a rapidly changing society
AND
Living and working in a health-promoting environment

11:00 – 11:45
Tackling diseases and reducing disease burden

Break

13:00 – 13:45
Ensuring equal access to innovative, sustainable, and high-quality healthcare
AND
Developing and using new tools, technologies and digital solutions for a healthy society

14:00 – 14:45
Maintaining an innovative, sustainable, and competitive EU health industry

European Commission

Overview

HORIZON-CL1-2025-01-CARE-XX

- 1 topic
- Single stage: opening 22 May 2025, closing16 Sept 2025
- Total budget: 40 MEUR (2 projects)

Impacts:

- Health and social care systems have improved governance, making them more effective, efficient, accessible, resilient, trusted and sustainable, both fiscally and environmentally
- people-centred and integrated healthcare structures, embedding technological innovations and prioritising health promotion and disease prevention
- Healthcare providers are trained and equipped with the skills and competences needed for future healthcare systems
- improved access to healthcare services, financial risk protection, timely access to quality healthcare services incl. essential medicines and vaccines
- Health policy and systems consider individuals, communities, organisations, society in interventions, healthcare organisation, and decision-making.

HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)

RIA, indicative budget 40 MEUR, 2 projects

Specificities: JRC may participate, subject to restrictions for the protection of European communication networks, lump sum, SSH

- user-centric, robust, trustworthy and ethical virtual assistant solutions based on Generative AI models and other AI tools to support healthcare professionals
- cross-country applicable methodologies
- multimodal health and research data, public knowledge, and reliable healthcare systems information
- Demonstrate the added-value and clinical utility of the virtual assistant solutions in at least two healthcare use cases in different medical fields and unmet needs
- Develop a regulatory strategy/interaction plan with regulators (incl. HTA) for generating evidence in a timely manner
- Develop or adapt existing methodologies for continuous assessment of the developed solutions (explainability, biases, errors and legal implications, etc.)
- encouraged to exploit potential synergies with the projects funded under the same topic, under topic HORIZON-CL4-2021-HUMAN-01-24, relevant European data infrastructures, etc. (foresee budget!)

Overview

HORIZON-CL1-2025-01-TOOL-XX

- 4 topics
- Single stage: opening 22 May 2025, closing16 Sept 2025
- Total budget: 220 MEUR

Impacts:

- Europe's scientific and technological expertise, capabilities for innovation and uptake of new tools, technologies and digital solutions, in healthcare is world-class (EU's visibility and leadership)
- Safer, more sustainable, efficient, cost-effective and affordable tools, technologies and digital solutions for improved (personalised) disease prevention, diagnosis, treatment and monitoring
- Innovative diagnostic and therapeutic approaches
- Improved, secure and ethical use of health data and innovative analytical tools
- Public trust

HORIZON-HLTH-2025-01-TOOL-01: Enhancing cell therapies with genomic techniques

RIA, indicative budget 50 MEUR, 5 projects

Specificities: JRC may participate, portfolio approach (therapeutic area), gender dimension, SME participation encouraged

- design of engineered cells to address the current limitations of cell therapies, e.g. delivery efficiency, patient safety, *in vivo* persistence, desired therapeutic effect, immune tolerance and manufacturing workflows
- Allogenic cells of human origin
- Use of genetic engineering /gene editing (genome, epigenome, introducing transgenes or artificial genes), incl. gene control systems (genetic switches, transcriptional/ post-transcriptional control, etc.)
- Theranostic cells
- Exogenous loading with drugs not in scope

HORIZON-HLTH-2025-01-TOOL-02: Advancing cell secretome-based therapies

RIA, indicative budget 40 MEUR, 3 projects

Specificities: JRC may participate, gender dimension, SME participation encouraged

- Build on already existing secretome-based therapies (mechanism already elucidated and therapeutic effect demonstrated)
- perform and finalise the phase 1 and phase 2 clinical trials during the lifetime of the project and further achieve authorization of the proposed therapy
- ensure regulatory and ethical approvals enabling the conduct of the clinical study, may incl. further pre-clinical studies and appropriate quality assurance
- Establishment of a manufacturing protocol for the selected secretome or its components, incl. definition of quality criteria for GMP production
- Defined timeline: M12: documentation for GMP production, M24: documentation for approval of clinical study

HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)

RIA, indicative budget 50 MEUR, 3 projects

Specificities: JRC may participate, gender dimension, subject to restrictions for the protection of European communication networks, SSH

- Develop new or re-purpose existing robust Generative AI models for biomedical research across various medical fields and/or therapeutic indications
- large-scale, complex, and multimodal high-quality real and/or synthetic data
- Develop a proof of concept with at least two use cases relevant for predictive and personalised medicine in different medical fields
- actively engage potential end users in the development, adaptation and testing models
- Develop or revise assessment methodologies: performance, explainability, usability, alignment with ethical principles, identifying and mitigating bias, privacy and discrimination risks
- encouraged to exploit potential synergies with relevant European data infrastructures, etc. (foresee budget!)

HORIZON-HLTH-2025-01-TOOL-05: Boosting the translation of biotech research into innovative health therapies

RIA, indicative budget 80 MEUR, 10 projects

Specificities: 5+ consortium members, >50% of budget to SMEs, max. duration 4 years, successful proposals receive the STEP seal

- In scope: biotechnology-derived therapies; out of scope: blood components or substances of human origin
- A Clinical study either phase I, II or I/II, depending on the appropriate stage of development
- demonstrate a significant economic potential of the final product(s) on the Single Market
- exploitation plan, with a detailed proposed route to commercialisation, description of the intellectual property ownership and benefit for the SME(s)
- Clinical indications where potentially large patient populations could benefit will be favoured.

Agenda

10:00 – 10:45
Staying healthy in a rapidly changing society
AND
Living and working in a health-promoting environment

11:00 – 11:45
Tackling diseases and reducing disease burden

Break

13:00 – 13:45
Ensuring equal access to innovative, sustainable, and high-quality healthcare
AND
Developing and using new tools, technologies and digital solutions for a healthy society

14:00 – 14:45
Maintaining an innovative, sustainable, and competitive EU health industry

European Commission

Overview

HORIZON-CL1-2025-01-IND-XX

HORIZON-CL1-2025-01-IND-XX-two-stage

- 3 topics
- 2 single stage: opening 22 May 2025, closing16 Sept 2025
- 1 two-stage: opening 22 May 2025, closing 1st stage 16 Sept 2025, 2nd stage 16 April 2026
- Total budget: 84 MEUR

Impacts:

- Health industry in Europe and Associated Countries is more competitive and sustainable, creating jobs and economic growth
- Health industry is working more efficiently along the value chain from the identification of needs to the scale-up and take-up of solutions
- Citizens, healthcare providers and health systems benefit from a swift uptake of innovative health technologies and services through the provision of evidence and guidelines for stakeholders, policymakers and regulators
- Increased health security in Europe and Associated Countries due to reliable access to key manufacturing capacity, essential medical supplies and critical supply and distribution chains.

HORIZON-HLTH-2025-01-IND-01: Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)

IA, indicative budget 40 MEUR, 5 projects

Specificities: JRC may participate, lump sum, SME participation strongly encouraged

- optimise the ATMP production where the general manufacturing process for a given medicinal product has already been established but has not been sufficiently optimised for its scale-up
- Exploring the potential of platform technologies in manufacturing, quality control, non-clinical or clinical testing
- Integrating either computational modelling, automation, robotics or digital/AI solutions with meaningful and measurable impact, verify the improved performance
- Demonstrate the translatability, scalability, and robustness of the process suitable for the flexible manufacturing
- as relevant, develop a regulatory strategy
- for generating appropriate evidence as well as engaging with regulators
- Green and sustainable production aspects

HORIZON-HLTH-2025-01-IND-02: Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices

CSA, indicative budget 4 MEUR, 1 project

Specificities: Coordinator must be established in an MS/AC, lump sum

- Feasibility study to digtalise the Conformity assessment procedure for Regulations on Medical Devices (MDR) and In Vitro Diagnostic Medical Devices (IVDR)
- Investigate existing initiatives to digitalise the procedure in the EU or in other jurisdictions (e.g. FDA)
- Identify main steps of the procedure to be digitalised, actors involved, and essential elements and requirements to be considered prior to digitalization
- Determine technical specifications and possible platforms
- Analyse facilitating factor and challenges and solutions
- Pilot and aggregate lessons learned, present alternatives and resources needed

HORIZON-HLTH-2025-03-IND-03-two-stage: Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative (“breakthrough”) devices

RIA, indicative budget 40 MEUR, 5 project

Specificities: blind evaluation, JRC may participate, subject to restrictions for the protection of European communication networks, lump sum, SSH, SME participation strongly encouraged

- multinational clinical studies of orphan devices and/or of breakthrough (major clinical benefit) devices, incl. digital and AI-based
- Design and conduct multinational clinical studies in a minimum of two different MS/AC to demonstrate the safety and clinical performance of the device(s), incl. clinical benefit and patient reported outcome
- Present a sound clinical study feasibility plan, incl. patient selection and recruitment plans, justified by scientific publications or prel. Results
- Develop a regulatory strategy and interaction plan (relevant national and international bodies)